Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

Oppenheimer analyst Jay Olson maintained a Buy rating on Revolution Medicines (RVMD – Research Report) today and set a price target of $45.00. The company’s shares closed yesterday at $37.17.

Olson covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, ACADIA Pharmaceuticals, and Incyte. According to TipRanks, Olson has an average return of 17.5% and a 43.18% success rate on recommended stocks.

Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $46.90, a 26.18% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $44.00 price target.

RVMD market cap is currently $6.13B and has a P/E ratio of -9.88.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revolution Medicines (RVMD) Company Description:

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.